Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Using Induction Chemoimmunotherapy as a Bridge to Definitive Local Therapy for Non-Metastatic NSCLC: Real-World Outcomes From a Comprehensive Cancer Center
AuthorsTroy J. Kleber; Sage A. Copling; Andrew D. Kim; César P. Márquez; Wenli Dong; Waree Rinsurongkawong; Vadeerat Rinsurongkawong; J. Jack Lee; Yuliya Kitsel; Xiaoyu Han; Sherif M. Ismail; Hui Xu; Ivan Coronado; Zhongxing Liao; Joe Y. Chang; Aileen Chen; Saumil Gandhi; Matthew S. Ning; Quynh-Nhu Nguyen; Michael S. O’Reilly; David Qian; James W. Welsh; Stephen G. Chun; Tina Cascone; Jianjun J. Zhang; Don L. Gibbons; Mehmet Altan; Ara A. Vaporciyan; David C. Rice; Ravi Rajaram; Reza J. Mehran; Mara B. Antonoff; Kyle G. Mitchell; Annikka Weissferdt; John V. Heymach; Jia Wu; Steven H. Lin; Julianna K. Bronk
AffiliationsDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; McGovern Medical School at UTHealth Houston., Houston, TX; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Imaging Physics, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX; Institute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Thoracic Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Thoracic-Head & Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Thoracic and Cardiovascular Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Anatomical Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non–small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial—HYPERBOLIC Study
AuthorsLudovica Mollica; Elena Tassi; Anna Copaloni; Irene De Simone; Roza Maria Barouni; Silvia De Giorgi; Antonella Pagano; Giacomo Lampertico; Maddalena Noviello; Michele Ferrara; Beatrice Garavaglia; Sara Guarnieri; Alessandra Bulotta; Maria Grazia Viganò; Francesca Rita Ogliari; Sara Oresti; Giuseppe Damiano; Vincenzo Russo; Silvia Teresa Riva; Antonio Nuccio; Fabio Salomone; Francesco Maria Venanzi; Francesco Passaretti; Ludovica Papotto; Denise Zotti; Anna Di Lello; Carmine Carbone; Emilio Bria; Antonella Sistigu; Martina Musella; Alberto Verlicchi; Paola Ulivi; Carlo Genova; Marco Tagliamento; Guido Ferlazzo; Giuseppe Lo Russo; Marta Brambilla; Giulia Pasello; Susanna Mandruzzato; Vincenzo Corbo; Sara Pilotto; Francesco De Sanctis; Alain Gelibter; Silvia Piconese; Marcello Tiseo; Giulia Mazzaschi; Monica Pluchino; Federico Cappuzzo; Gabriele Minuti; Lorenza Landi; Paola Nisticò; Hugo Arasanz; Ibone Labiano; Laura Mezquita; Mariona Pascal; Pernelle Lavaud; Nathalie Chaput; Salvatore Grisanti; Anna Cecilia Bettini; Diego Luigi Cortinovis; Giulia Galli; Nicla La Verde; Stefano Panni; Wanda Liguigli; Fausto Petrelli; Antonio Santo; Diego Signorelli; Gianluca Tomasello; Luca Toschi; Chiara Catania; Giuseppina Rita Di Fazio; Elisa Anselmi; Andrea De Giglio; Andrea Ardizzoni; Chiara Bennati; Stefano Indraccolo; Marco Genua; Renato Ostuni; Matteo Bellone; Nicola Clementi; Antonio Esposito; Francesco De Cobelli; Diego Palumbo; Anna Damascelli; Francesco Prato; Stefano De Pretis; Dejan Lazarević; Eliana Ruggiero; Maurilio Ponzoni; Gianluigi Arrigoni; Federica Pedica; Giulia Veronesi; Mario Paolo Colombo; Eliana Rulli; Valter Torri; Matteo Sacco; Marina Chiara Garassino; Benjamin Besse; Michele Reni; Stefano Cascinu; Fabio Ciceri; Chiara Bonini; Sabina Sangaletti; Roberto Ferrara
AffiliationsDepartment of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy; Cell Therapy Immunomonitoring Laboratory (MITiCi), Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy; Methodology for Clinical Research Laboratory, IRCCS Mario Negri Institute for Pharmacological Research, Milan, Italy; San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, San Raffaele Scientific Institute, DIBIT, Milan, Italy; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; Comprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Medical Oncology Unit, Ospedale Isola Tiberina – Gemelli Isola, Rome, Italy; Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy; Department of Medical Oncology, IRCCS Istituto Romagnolo per Lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy; Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy; Department of Internal Medicine and Medical Specialties, University of Genova, Genova, Italy; Academic Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Experimental Medicine, University of Genova, Genova, Italy; Unit of Experimental Pathology and Immunology, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Department of Engineering for Innovation Medicine (DIMI), University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy; Department of Medicine, Section of Immunology, University of Verona, Verona, Italy; Division of Oncology, Department of Radiological, Oncological and Pathological Science, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy; Department of Translational and Precision Medicine, “Sapienza” University of Rome, Rome, Italy; Department of Medicine and Surgery, University of Parma, Parma, Italy; Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy; Clinical Trials Unit Phase I and Precision Medicine IRCCS Regina Elena National Cancer Institute, Rome, Italy; Tumor Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy; Medical Oncology Department, Hospital Universitario de Navarra – Oncoimmunology, Navarrabiomed, Pamplona, Spain; Translational Medical Oncology Unit, Navarrabiomed – IdiSNA, Pamplona, Spain; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain; Servei d'Immunologia, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain; Department of Cancer Medicine, Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Paris-Saclay University, Villejuif, France; Laboratoire d'Immunomonitoring en Oncologie, Université Paris Saclay, Unité US-23 INSERM, UMS-3655 CNRS, Gustave Roussy, Villejuif, France; Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Brescia, Italy; Medical Oncology, ASST Papa Giovanni XXIII, Bergamo, Italy; Fondazione IRCCS San Gerardo dei Tintori, Università degli Studi di Milano-Bicocca, Monza, Italy; Department of Oncology, Comprehensive Cancer Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Oncology, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy; Oncology Division, ASST Ospedale di Cremona, Cremona, Italy; Oncological Department, Poma Hospital, Mantova, Italy; Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy; Oncologia Toracica, Lung Unit, Ospedale P. Pederzoli, Peschiera del Garda, Italy; Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; Oncology Unit, ASST Crema, Crema, Italy; Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy; Division of Medical Oncology, Humanitas Gavazzeni, Bergamo, Italy; Medical Oncology Unit, Fatebenefratelli Hospital, ASST Fatebenefratelli Sacco, Milan, Italy; Oncology and Hematology Department, Piacenza General Hospital, Piacenza, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical Oncology, Santa Maria Delle Croci Hospital, Ravenna, Italy; Basic and Translational Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Cellular Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy; Laboratorio di Microbiologia e Virologia, IRCCS Ospedale San Raffaele, Milan, Italy; Laboratorio di Microbiologia e Virologia, Università Vita-Salute San Raffaele, Milan, Italy; Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Center for Omics Sciences, IRCCS San Raffaele Scientific Institute-Vita-Salute San Raffaele University, Milan, Italy; Experimental Hematology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Thoracic Surgery, IRCCS San Raffaele Scientific Institute, Milan, Italy; Molecular Immunology Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori di Milano, Milan, Italy; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA; Hematology and Bone Marrow transplant Unit, San Raffaele Scientific Institute IRCCS, Milan, Italy
Assessing Guideline-Directed Care in the New Era of Neoadjuvant Therapy in Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): A Retrospective Review
AuthorsAlisha P. Maity; Stephanie Kjelstrom; Hongyan Gu; Matthew Sanborn; Akshar Kalola; Deric Savior; Arezoo Ghaneie; Scott K. Dessain
AffiliationsDepartment of Hematology/Oncology, Lankenau Medical Center, Wynnewood, PA; Lankenau Institute for Medical Research, Wynnewood, PA; Main Line Health IT Services, Reporting Team, Radnor, PA
Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass)
AuthorsRichard Riedel; Malte Verheyen; Sebastian Michels; Lea Ruge; Sofia Stilianakis; Carolin Jakob; Heather Scharpenseel; Matthias Scheffler; Lucia Nogova; Karsten Schulmann; Farastuk Bozorgmehr; Christian Grohe; Frank Griesinger; Vanessa Welter; Jana Fassunke; Janna Siemanowski-Hrach; Yuri Tolkach; Udo Siebolts; Sabine Merkelbach-Bruse; Reinhard Büttner; Jürgen Wolf; Felix John
AffiliationsDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; Division of Thoracic Oncology and Palliative Care, Department of Pneumology, Lungenklinik Hemer, Hemer, Germany; Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital and National Center for Tumor Diseases (NCT), Heidelberg, Germany; Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin, Germany; Department of Haematology and Oncology, Pius-Hospital Oldenburg Medical Campus, Oldenburg, Germany; Faculty of Medicine and University Hospital of Cologne, Institute for Pathology, University of Cologne, Cologne, Germany
Consolidative Hypofractionated Radiotherapy for Oligometastatic Non–Small-Cell Lung Cancer
AuthorsJongmoo Park; Min Kyu Kang; Shin Yup Lee; Seung Soo Yoo; Sun Ha Choi; Jae Yong Park; Young Woo Do; Eung Bae Lee; Shin Young Jeong; Moonsik Kim; Bong Kyung Bae
AffiliationsDepartment of Radiation Oncology, School of Medicine, Kyungpook National University, Daegu, Korea; Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea; Department of Thoracic Surgery, School of Medicine, Kyungpook National University, Daegu, Korea; Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Korea; Department of Pathology, School of Medicine, Kyungpook National University, Daegu, Korea
Prolonged Disease Control on Tepotinib in a Patient With HLA-DRB1-MET-Positive Metastatic Non–small Cell Lung Cancer: The Role of RNA Sequencing and Targeted Therapy for Rare MET Rearrangements
AuthorsJason Y. Chang; Gauri Kelekar; Mon Miyakawa-Liu; Heather A. Wakelee; Nathaniel J. Myall
AffiliationsDepartment of Medicine, Stanford University School of Medicine, Stanford, CA; Sutter Health, California Pacific Medical Center (CPMC), San Francisco, CA; Department of Pathology, Stanford University School of Medicine, Stanford, CA; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
Impact of Socioeconomic Status on Patient-Reported Outcomes (PROs) in Non–Small-Cell Lung Cancer (NSCLC)
AuthorsBindu Potugari; Jaya Gupta; Julia Bachler; Anqi Wang; Eric Adjei Boakye; Samantha Tam; Theresa Zatirka; Benjamin Movsas; Shirish Gadgeel
AffiliationsDivision of Hematology/Oncology, Department of Internal Medicine, Henry Ford Health, Detroit, MI; Division of Palliative Medicine, Department of Medicine, Henry Ford Health, Detroit, MI; Department of Public Health Sciences, Henry Ford Health, Detroit, MI; Department of Otolaryngology – Head and Neck Surgery, Henry Ford Health, Detroit, MI; Henry Ford Cancer, Henry Ford Health, Detroit, MI; Department of Radiation Oncology, Henry Ford Health, Detroit, MI
Immunotherapy in Patients With Small-Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome: A Multi-institutional Case Series
AuthorsKübra Canaslan; Ditte Primdahl; Wade Iams; Cassidi Lugo; Karan Dixit; Hafeez Chatoor; Ticiana Leal; Shailee Shah
AffiliationsDepartment of Medical Oncology, Dokuz Eylul University, Izmir, Turkiye; Department of Neurology and Neurological Surgery, Northwestern University, Chicago, IL; Greco Hainsworth Centers for Research, Tennessee Oncology, Nashville, TN; Department of Medical Oncology, Florida Cancer Specialist and Research Institute, Tampa, FL; Division of Neuro-Oncology, Department of Neurology, Feinberg School of Medicine Northwestern University, Chicago, IL; Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; Department of Neurology, Northwestern University, Chicago, IL; Department of Neurology, Vanderbilt University, Chicago, IL
Incidence of Radiation Pneumonitis Following EGFR-TKI Combined With Thoracic Radiotherapy in Unresectable Stage III or IV Non–Small-Cell Lung Cancer: A Systematic Review and Meta-analysis
AuthorsYuhao Yao; Xiao Xia; Lanxin Zhang; Shuaihang Hu; Dandan Wang; Wei Hou
AffiliationsGraduate School, Beijing University of Chinese Medicine, Beijing, China; Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China; Department of Cardiology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
An Observational Population Level Study of Neoadjuvant Chemoimmunotherapy for Resectable Non–Small-Cell Lung Cancer
AuthorsSiddhartha Goutam; Amanda J.W. Gibson; Michelle Liane Dean; Abigail R. Miller; Bianca Rosin de Oliveira; Vishal Navani
AffiliationsDepartment of Oncology, Arthur J.E. Child Comprehensive Cancer Center, Calgary, Alberta, Canada; Glans-Look Lung Cancer Research (GLR) Program, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
